



PRESS RELEASE

Date 7 April 2017
Contact Investor Relations: Felix Burkhard, CFO, Galenica Santé
Media Relations: Christina Hertig, Head Corporate Communications, Galenica Santé
Subject Listing of Galenica Santé on SIX Swiss Exchange

Galenica Santé lists on SIX Swiss Exchange

Today marks the start of Galenica Santé, the leading fully-integrated healthcare provider in Switzerland, as an independent, newly listed company. Galenica Group accelerated the closing of the bookbuilding process for the initial public offering (IPO) of Galenica Santé by one day to 5 April 2017 and today fixed the offer price at CHF 39.00 per share. It is therefore at the top end of the originally defined price range of CHF 31.00 to CHF 39.00, which was narrowed on 3 April 2017 to CHF 37.00 to CHF 39.00. The offer was several times oversubscribed during the bookbuilding period. The shares of Galenica Santé (SIX: GALE) will be listed and trading will commence on SIX Swiss Exchange today, 7 April 2017.

At the offer price of CHF 39.00 per share, the market capitalisation of Galenica Santé is CHF 1,950 million, with the offer several times oversubscribed during the bookbuilding period. Upon full exercise of the over-allotment option, the free float of Galenica Santé amounts to 97.5%. Galenica Group sold 42,391,300 shares in the offering. In addition, Galenica Group granted the syndicate banks an over-allotment option of up to an additional 6,358,700 shares, which were also sold.

Galenica Group will not hold any more shares of Galenica Santé in future. The remaining shares, amounting to 2.5% of the share capital of Galenica Santé, are reserved for the exchange of Galenica Group shares into Galenica Santé shares for eligible employees of Galenica Santé.

Following the strong demand, Galenica Santé has a broadly diversified shareholder base consisting of both institutional and private as well as Swiss and international investors, with voting rights capped at 5% in principal. This gives Galenica Santé an ideal starting point to continue to develop and offer its services to all partners in the Swiss healthcare market as an autonomous and independent company in the future as well.

"Our range of offerings and services for all participants in the healthcare market makes us the leading health services provider in Switzerland. Building on our strengths, the IPO on SIX Swiss Exchange will enable Galenica Santé to pursue its strategy in an even more focused way. We and our employees have the opportunity to further develop our unique position – with our own and partner pharmacies, our own brands and partner products, and our expertise in logistics," explains Jean-Claude Cléménçon, CEO Galenica Santé.

At the Annual General Meeting of Galenica Group on 11 May 2017, shareholders will vote on the name change of Galenica Group to Vifor Pharma Group. As a result it is expected that as of 12 May 2017, Galenica Santé will be renamed Galenica.

Date 7 April 2017
Page 2/3
Subject Listing of Galenica Santé on SIX Swiss Exchange

Key data

Listing	SIX Swiss Exchange (International Reporting Standard)
Ticker symbol	GALE
Swiss security number	36 067 446
ISIN	CH036 067 446 6
Total number of ordinary registered shares	50,000,000
Nominal Value	CHF 0.10 per registered share
Offer price	CHF 39.00 per share
Offering	Base offer of 42,391,300 shares
	Over-Allotment Option of 6,358,700 additional registered shares
Anticipated schedule	
Listing and first day of trading	7 April 2017
Book-entry delivery of offered shares against payment of the offer price	11 April 2017
Last day for exercising the over-allotment option	5 May 2017

Copies of the Offering Memorandum and the Supplement may be obtained free of charge from Credit Suisse AG, Zurich, Switzerland (email: equity.prospectus@credit-suisse.com) and from UBS AG, Zurich, Switzerland (email: swiss-prospectus@ubs.com).

Dates for the diary

Galenica Santé will present its half-year results 2017 on 8 August 2017.

For further information, please contact:

Media Relations:

Christina Hertig, Head Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Investor Relations:

Felix Burkhard, CFO
Tel. +41 58 852 85 29
E-mail: investors@galenica.com

Galenica Santé is the leading fully-integrated healthcare provider in Switzerland. With nearly 500 own, joint venture and independent partner pharmacies, Galenica Santé operates the largest network of pharmacies in Switzerland. In addition, Galenica Santé further develops and offers well-known own brands and products, exclusive brands and products from business partners as well as a variety of on-site health services and tests for customers. Galenica Santé is also the leading provider of pre-wholesale and wholesale distribution as well as database services in the Swiss healthcare market. Galenica Santé is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446).

Additional information concerning the Galenica Santé can be found at www.galenica.com.

Date 7 April 2017
Page 3/3
Subject Listing of Galenica Santé on SIX Swiss Exchange

Disclaimer

This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. This document is not a prospectus within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. A decision to invest in securities of Galenica Santé AG (the "Company") should be based exclusively on the issue and listing prospectus to be published by the Company for such purpose.

This document and the information contained herein are for information purposes only and do not constitute a prospectus or an offer to sell, or a solicitation of an offer to buy, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or pursuant to an available exemption from registration under the Securities Act. Neither Galenica Santé AG (the "Company") nor its shareholder intends to register any securities referred to herein in the United States.

The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is being communicated only to (i) persons who are outside the U.K.; (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (iii) high net worth companies, unincorporated associations and other bodies who fall within article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This document should not be published, reproduced, distributed or otherwise made available, in whole or in part, to any other person without the prior consent of the Company.

Any offer of securities to the public that may be deemed to be made pursuant to this communication in any member state of the European Economic Area (each an "EEA Member State") that has implemented Directive 2003/71/EC (together with the 2010 PD Amending Directive 2010/73/EU, including any applicable implementing measures in any Member State, the "Prospectus Directive") is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.

The Joint Bookrunners and Co-Lead Managers are acting exclusively for the Company and no-one else in connection with the Offering. They will not regard any other person as their respective clients in relation to the Offering and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in relation to the Offering, the contents of this announcement or any transaction, arrangement or other matter referred to herein.

This document contains forward-looking statements. These statements are based on the current views, expectations, assumptions and information of the management of the Company. Forward-looking statements should not be construed as a promise of future results and developments and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those described in such statements due to a number of factors. The Company does not assume any obligations to update any forward-looking statements.